{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:22:04Z","timestamp":1750537324721},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamaoncol.2018.6431","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T04:26:51Z","timestamp":1548390411000},"page":"730","source":"Crossref","is-referenced-by-count":2,"title":["Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy"],"prefix":"10.1001","volume":"5","author":[{"given":"Joanna","family":"Mangana","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline S.","family":"Buset","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"26","key":"ccg180011r1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"ccg180011r2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents.","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"ccg180011r3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CCO.0000000000000358","article-title":"A review of serious adverse effects under treatment with checkpoint inhibitors.","volume":"29","author":"Heinzerling","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"ccg180011r4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"ccg180011r5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression.","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"ccg180011r6","first-page":"263","article-title":"Drug-induced panniculitides.","volume":"149","author":"Borroni","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"3","key":"ccg180011r7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment.","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"issue":"1","key":"ccg180011r8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdcr.2017.06.014","article-title":"Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy.","volume":"4","author":"Jiang","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"7","key":"ccg180011r9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","article-title":"Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum.","volume":"153","author":"Burillo-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"ccg180011r10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1067\/mjd.2001.114735","article-title":"Panniculitis. part ii. mostly lobular panniculitis.","volume":"45","author":"Requena","year":"2001","journal-title":"J Am Acad Dermatol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/5\/730\/17575059\/jamaoncology_mangana_2019_cg_180011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T07:16:37Z","timestamp":1573802197000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.6431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.6431","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}